Latest News and Press Releases

ZURICH, Switzerland, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) is proud to...

Completing Production Pilot for Generation 2 of AptameX™ as a Precursor to Mass Commercial ProductionExpect to Commence Delivery to Sales and Marketing Contract with Nahdlatul Ulama on Commencement of...

ZURICH, Switzerland, June 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...

Registered AptameX and Has Obtained a CE Mark, Allowing the Product to Be Sold in 27 Countries in the EUAptameX Has Unique Performance Advantages Over Other Rapid Tests Through its Use of DNA...

Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...

ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the...

Unique Chemistry with DNA Aptamers Completing Pre-Sales Validation TestingCompleting Pre-Sales Validation Testing in Indonesia ZURICH, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Ad...

Second-generation of AptameX, Achiko’s innovative DNA aptamer diagnostic test for Covid-19 has received full approval in Indonesia for five yearsProduction of the second-generation AptameX kits to...

Pilot program in Indonesia is on track with positive results and support for Achiko’s proprietary, low-cost rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service...

After receiving product and registration approval from Indonesia’s Ministry of Health in August, Achiko is positioned to produce up to a million AptameX test kits in Q4 2021, and more if the supply...